X
J&J bulks up in bispecifics with $1.3bn Xencor alliance
https://pharmaphorum.com/news/jj-bulks-up-in-bispecifics-with-1-3bn-xencor-alliance/
Xencor
Novartis buys into bispecific antibodies with Xencor deal
Agreement could add to Novartis’ immuno-oncology pipeline.